RxDoctor Payments Data

Nidal Makhoul, MD

Nuclear Cardiology · Plattsburgh, NYNPI 1063409282

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Merck at 31.0% of the total. Reporting peaked in 2022 at $134 and has fallen 81.9% since, to $24 in 2024. That places this record below the midpoint for nuclear cardiology clinicians in NY, where the typical reported total is $1,470.

$258in general payments, 2019–2025

Across 8 payments — averaging $32.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$80
  • Medtronic$63
  • Pfizer$54
  • Philips North America LLC$24
  • Kiniksa Pharmaceuticals, Ltd.$20
  • Mannkind Corporation$17

What the payments were for

  • Food & beverage$258100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$258 in reported general payments places this provider in the 30th percentile of 21 nuclear cardiology providers in New York.

See all nuclear cardiology providers in New York

Medicare billing

Part B allowed, 2024
$139,804
Medicare patients
1,262
Services billed
2,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$118,352
EntrestoSacubitril/Valsartan32$36,754
XareltoRivaroxaban17$22,323
Repatha SureclickEvolocumab15$19,507
Praluent PenAlirocumab13$6,415
Ranolazine ErRanolazine45$3,643
Metoprolol Succinate89$1,009
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$363
Atorvastatin Calcium52$354
Lisinopril32$179
Amlodipine Besylate26$172
Warfarin Sodium15$167
Ezetimibe13$166
Losartan Potassium13$134
Carvedilol22$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$54$118,35284 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 21 nuclear cardiology providers in New York.

Other nuclear cardiology in Plattsburgh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →